Half a century of basic research and clinical trials has failed to provide an agreed and acceptable method of preventing thrombotic arterial occlusion. Indeed, it has been suggested that recent trials have fed the fires of controversy rather than quelling them, and to understand this paradox we must remind ourselves of the origin of the clinical trial concept. Early trials were done in diseases whose cause was known so that all that was under scrutiny was the ability of a regimen to remove or modify that cause. Tuberculosis was known to be caused by Koch's bacillus, so the only question was whether drugs such as streptomycin, which affected bacterial growth in vitro, could safely kill the organism in the lungs of tuberculous patients. Similarly, the viral cause of poliomyelitis was not in doubt, so clinical trials could begin from a secure base and could explore whether Salk or Sabin vaccines conferred the best protection.
In sharp contrast, we have no idea how thrombi form and the ritual murmuring of "Virchow's triad" should merely remind us that though there may well be abnormalities of flow, of the wall or of the and test a new concept of causation. In this brief review, I will examine the ways in which theories about causation and the models of disease we have constructed from them have dictated the conduct of trials. I shall show how so-called "basic research" has been used to design trials, whereas we may well stumble on to something that works by serendipity and empiricism and only later find out how it works.
How models have dictated trial design ( 
1) ATHEROMA CAUSES THROMBOSIS
The close association between wall disease and thrombotic occlusion led Virchow' and many of his successors to assert that the cause of thrombosis was atherosclerosis. If so, by finding the cause of atheroma, and removing it, thrombosis would cease to be a problem. Theoretical considerations and inappropriate animal models led to a wide assortment of conflicting causal hypotheses (lipid infiltration; mechanical damage from hypertension; inflammation; chemical damage from cigarette smoke; tumour formation; mucopolysaccharide abnormalities). The only acceptable evidence of a direct influence of regimens designed to modify these postulated mechanisms would be to observe the regression or non-progression of plaques in man and this evidence is now being collected2; a reduction in clinical end-points might merely mean that other target organs were being protected (the heart against fatal arrhythmias by the beta-blockers which are being used to lower blood pressure) or that other systems were being modified (the platelets by lipid lowering diets which also shift thromboxane/prostacyclin balance). So far our direct attacks on atheroma have got us precisely nowhere. (a) Thrombosis is clotting in the wrong place When blood is shed from the body it solidifies because of the activation of two enzymic cascades (the extrinsic system is quicker and is triggered when trauma adds tissue juices to the blood; the intrinsic system is slower and is activated by exposure to foreign surfaces). The idea that a plaque could exude tissue juice or that its ragged lining could act as a foreign surface led to the hope that anticoagulants, which prevent the formation of protein clotting factors in the extrinsic system (Factor VII), the intrinsic system (Factor IX), or their final common path (II and X), would modify thrombus formation. In the veins, they undoubtedly do,5 so venous thrombosis may indeed* be clotting in the wrong place. In the arterial tree, however, initial confidence and optimism gave way to doubt and rejection when the poor quality of the trials became apparent. Nevertheless, when the anticoagulant era whimpered to its close in the 1960's, the best trials had shown that long term treatment did significantly reduce mortality after myocardial infarction6 but optimism about newer lines of-treatment swept this benefit under the carpet. We are now paying the price for premature abandonment, because in healthy subjects, clotting factors have been shown to be a better predictor of subsequent myocardial infarction than lipid levels.7 Furthermore, a Dutch group8 have shown a tantalising but not statistically significant reduction in total mortality, when analysed on an intention-to-treat basis, in a group of subjects who continued taking anticoagulants after infarction as opposed to a group who stopped taking them. Recurrent infarction, but not sudden death, was the end-point which changed most, and there was also a suggestion that thrombotic cerebral disease was reduced. The concept that venous thrombosis is clotting in the wrong place, whereas arterial thrombosis is totally divorced from clotting is thus an oversimplification, and the difference between them may be a matter of degree and not of kind. The earlier evidence, however, had already led trialists, disillusioned with anticoagulation, to dismiss clotting and to formulate a platelet-driven, rather than a clotting-driven, hypothesis.
(b) Thrombosis is haemostasis in the wrong place When a vessel is injured, initial haemostasis is rapidly secured by a platelet plug, and only later does a fibrin Mitchell scaffold stabilise the mass. The plug forms far too quickly for it to be attributable to the more leisurely clotting cascade, so attention began to be focused on simple and universally distributed substances, unrelated to clotting factors, which stimulated platelet aggregation (first, adenosine diphosphate9; then adrenaline, noradrenaline, and 5-hydroxytryptamine'0; finally, collagen"). It was postulated that platelet aggregation and the subsequent release of supplies of aggregating agents stored in platelets could provide a powerful and self-amplifying system by which a thrombus could be generated and grow, so a search was made for potential drugs that would modify these aspects of platelet behaviour. Serendipity came to our aid, for three agents, widely used for other indications, and therefore of proven safety, were shown to modify platelet activities (the vasodilator, dipyridamole' 2; the uricosuric, sulphinpyrazone,'3 and the panacea for all bodily ills, aspirin'4). Many major trials have now been performed to determine whether these agents can prevent spontaneous thrombosis (as opposed to thrombosis on foreign surfaces, such as prosthetic valves or dialysis shunts). Dipyridamole alone seems ineffective, aspirin alone has shown benefit, harm, or neutrality in various post-infarction trials,'5 and has given a hint of benefit in Canada for men with transient ischaemic attacks but not for women,16 while conferring no significant benefit on either sex in the United States.'7 The sulphinpyrazone post-infarction trials have generated controversy'8 rather than clear-cut conclusions, but it should be remembered that the most favourable outcome in the Canadian transient ischaemic attack study was in men receiving both aspirin and sulphinpyrazone. 16 oxygenase converts arachidonic acid into the cyclic endoperoxides PGG2 and PGH2 and thromboxane synthetase then transmutes them into thromboxane A2. Could an excess of thromboxane A2 be the cause of thrombosis? If so, why had aspirin, which irreversibly acetylates cyclo-oxygenase,20 thereby stopping thromboxane A2 production, not proved to be antithrombotic? It was found that the vessel walls were using a similar pathway to generate the powerful anti-aggregant vasodilator, prostacyclin2 I so that aspirin was blocking the crucial cyclo-oxygenase step common to bothl the generation of "good" prostacyclin and well as "bad" thromboxane A2. Vessel walls can synthesise new enzyme, whereas platelets cannot, so it was suggested that "low dose" or "pulsed dose" aspirin might allow the "shining white knight" in the vessel wall to escape unharmed while keeping the "evil black dragon" in the platelets a permanent prisoner. In our hands,22 as in those of others,23 there appears to be no single regimen of aspirin which reliably suppresses thromboxane A2 production in all subjects, while retaining reasonable levels of vessel wall prostacyclin. If such a dose exists, it is probably 40 mg (or half a junior aspirin tablet) every third day, which must bring comfort to those trialists who are in the middle of major studies using "low dose aspirin" at 300 mg per day. There are thus too many questions chasing too few centres with the patients and the patience, the will, the skill, and the resources to answer them. In common conditions such as myocardial infarction, which kills 160 000 people each year in England and Wales, or stroke which slaughters 80 000, it is a damning indictment of clinical freedom (which is the right of a clinician to do anything, provided only that he believes it to be of benefit), that we cannot order our affairs better. If only we could answer one question at a time properly, as opposed to browsing here, nibbling there, and then trampling the rest of the vegetation underfoot.
As Fredrickson said,27 trials "continue to be an ordeal. They lack glamour, they strain our resources and our patience, and they protract the moment of truth to excruciating limits. They are among the most challenging tests of our skills, and if, in major dilemmas, the alternative is to pay the cost of perpetual uncertainty, have we any choice?" Remember, theoretical models generate the hypotheses which lead to clinical trials, but at the end of the day it is the outcome of those trials which will make or break the hypotheses, for, as Huxley pointed out last century, "The tragedy of science is the slaying of a beautiful hypothesis by ugly facts". 
